Another busy week is on deck for the IPO markets as there looks to be six offerings on the calendar. All totaled up it looks like the six companies will try and raise a total of $1.2 billion. This week will may get more media attention thanks to the TV streaming service Roku. Other names looking to go public fall in the Chinese education space as well as a chemical maker, and three biotech companies.

First up, we'll talk about what could be the most focused on IPO, and that is Roku (ROKU  ). The company runs a TV streaming platform based only in the US and currently has over 5000 channels. They will hope to raise $204 million by offering up just over 15 million shares at a price range of $12 - 14. This will also be a further glimpse into the swelling trend of cord cutting here in the states.

Next is PQ Group Holdings (PQG  ) which has the potential to be the largest offering of the week. The global producer of catalysts and other inorganic chemicals will look to raise $638 million. Thy are offering 29 million shares to the public at a range of $21 - 23. Though revenue has declined in the last quarter, analysts note the history of high EBITDA margins, right around 30%.

RYB Education (RYB  ) is a leading provider of early childhood education company based in China. They hope to raise $133 million by offering 7.8 million shares to the public at a range of $16 - 18.

NuCana (NCNA  ) is a UK based biotech company that is focused on developing enhanced chemotherapies for resistant tumors. The company believes that it's "ProTide" technology can improve the efficiency and safety of common chemotherapies. They hope to raise $100 million and are offering 6.6 million shares at a range of $14 - 16.

Nightstar Therapeutics (NITE  ) is coming to market looking for $75 million. They are offering 5.3 million shares at a range of $13 - 15 in hopes of continuing to develop their gene therapies for rare retinal diseases.

Lastly, we have Deciphera Pharmaceuticals (NASDQ: DCPH) which is a clinical state biotech with a focus on kinase inhibitors for solid tumors. They are looking for $100 million and will be offering 6.2 million shares at a range of $15 - 17.